[Clinical observations during accumulative oral glycoside therapy with meproscillarin (author's transl)].
In heart failure of the severity degrees II and III according to Friedberg's classification, administration of a daily maintenance dose of 0.5--0.75 mg of 14-hydroxy-3beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (mesproscillarin, Clift) induces a cumulative blood level of 1--1.5 mg after 8--10 days. This level eliminates manifestations of heart failure both clinically and with regard to objective criteria. Increased heart rate returns to normal particularly in types of the tachycardiac atrial fibrillation. The frequency corrected QT-time is significantly reduced by about 30 ms. The relative heart volume decreases. The heart's work is increased by about 15%. No side effects are observed under this oral accumulative glycoside therapy.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002301:Cardiac Glycosides / Q000494:pharmacology / Q000627:therapeutic use*; D002302:Cardiac Output / Q000187:drug effects; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged
D002301:Cardiac Glycosides
Klinische Beobachtungen während einer akkumulativen oralen Glykosidtherapie mit Meproscillarin.